NASDAQ:ALDX Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free ALDX Stock Alerts $3.08 +0.16 (+5.48%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$2.89▼$3.1450-Day Range$2.77▼$4.2252-Week Range$1.42▼$11.97Volume309,879 shsAverage Volume494,710 shsMarket Capitalization$181.41 millionP/E RatioN/ADividend YieldN/APrice Target$12.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Aldeyra Therapeutics alerts: Email Address Aldeyra Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside300.4% Upside$12.33 Price TargetShort InterestHealthy3.24% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingSelling Shares$365,194 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.26) to ($0.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.96 out of 5 starsMedical Sector401st out of 939 stocksPharmaceutical Preparations Industry186th out of 425 stocks 3.3 Analyst's Opinion Consensus RatingAldeyra Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.33, Aldeyra Therapeutics has a forecasted upside of 300.4% from its current price of $3.08.Amount of Analyst CoverageAldeyra Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.24% of the float of Aldeyra Therapeutics has been sold short.Short Interest Ratio / Days to CoverAldeyra Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aldeyra Therapeutics has recently decreased by 5.67%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAldeyra Therapeutics does not currently pay a dividend.Dividend GrowthAldeyra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALDX. Previous Next 3.9 News and Social Media Coverage News SentimentAldeyra Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aldeyra Therapeutics this week, compared to 2 articles on an average week.Search Interest15 people have searched for ALDX on MarketBeat in the last 30 days. This is an increase of 88% compared to the previous 30 days.MarketBeat Follows7 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aldeyra Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $365,194.00 in company stock.Percentage Held by InsidersOnly 7.30% of the stock of Aldeyra Therapeutics is held by insiders.Percentage Held by Institutions59.71% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aldeyra Therapeutics are expected to decrease in the coming year, from ($0.26) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aldeyra Therapeutics is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aldeyra Therapeutics is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAldeyra Therapeutics has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Huge AlertsTrending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! Click To Get Our Next Alert About Aldeyra Therapeutics Stock (NASDAQ:ALDX)Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Read More ALDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALDX Stock News HeadlinesMarch 13, 2024 | insidertrades.comBruce Greenberg Sells 13,201 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) StockMarch 22, 2024 | americanbankingnews.comReviewing Bolt Biotherapeutics (NASDAQ:BOLT) & Aldeyra Therapeutics (NASDAQ:ALDX)March 28, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 13, 2024 | finance.yahoo.comAldeyra Therapeutics Inc President and CEO Todd Brady Sells Company SharesMarch 11, 2024 | markets.businessinsider.comStrong Buy Rating for Aldeyra Therapeutics Backed by Reproxalap Developments and Strategic PartnershipsFebruary 22, 2024 | finance.yahoo.comInstitutions own 37% of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares but retail investors control 37% of the companyFebruary 14, 2024 | cnn.comIntellia Therapeutics, Inc.February 6, 2024 | finance.yahoo.comAldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceMarch 28, 2024 | DTI (Ad)CBOE shift unlocks new weekend income strategyYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend. January 31, 2024 | benzinga.comAldeyra Therapeutics Stock (NASDAQ:ALDX), Guidance and ForecastJanuary 28, 2024 | seekingalpha.comWhy Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's ProspectsJanuary 4, 2024 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Aldeyra Therapeutics, Inc. (ALDX)January 4, 2024 | finance.yahoo.comAldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory DiseasesDecember 31, 2023 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Aldeyra Therapeutics (ALDX)December 21, 2023 | markets.businessinsider.comOutperform Rating Affirmed on Aldeyra Therapeutics Following Positive ADX Developments and Expanding Treatment ProspectsDecember 21, 2023 | markets.businessinsider.comBuy Rating Affirmed for Aldeyra Therapeutics Amidst Clinical Advancements and Market PotentialDecember 19, 2023 | msn.comPositive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis StudyDecember 19, 2023 | marketwatch.comAldeyra Therapeutics Shares Rise 12% Following Positive Trial Results of ADX-629December 19, 2023 | seekingalpha.comAldeyra stock jumps 8% on dermatitis drug updatesDecember 19, 2023 | reuters.comAldeyra Therapeutics' skin disease drug succeeds in mid-stage studyDecember 19, 2023 | finance.yahoo.comAldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic DermatitisDecember 18, 2023 | finance.yahoo.comAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic DermatitisDecember 16, 2023 | msn.comAldeyra Therapeutics (ALDX) Price Target Increased by 13.56% to 11.39December 5, 2023 | finance.yahoo.comShould You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings?November 28, 2023 | bizjournals.comLexington biotech gets second FDA rejection this yearNovember 28, 2023 | msn.comFDA Rejects Aldeyra Therapeutics' Dry Eye Disease Candidate, Asks For Additional StudyNovember 27, 2023 | msn.comFDA says more data needed to approve Aldeyra dry eye drug (update)See More Headlines Receive ALDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/27/2021Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALDX CUSIPN/A CIK1341235 Webwww.ampliphibio.com Phone781-761-4904Fax781-270-0630Employees15Year FoundedN/APrice Target and Rating Average Stock Price Target$12.33 High Stock Price Target$15.00 Low Stock Price Target$8.00 Potential Upside/Downside+300.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.45% Return on Assets-24.24% Debt Debt-to-Equity RatioN/A Current Ratio6.64 Quick Ratio6.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book1.51Miscellaneous Outstanding Shares58,900,000Free Float54,597,000Market Cap$181.41 million OptionableOptionable Beta1.53 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesTodd C. Brady (Age 48)M.D., Ph.D., Chief Executive Officer and Director Joshua Reed (Age 47)Chief Financial Officer David McMullin (Age 45)Chief Commercial Officer James A. Gow (Age 53)M.D., Senior Vice President of Clinical Development Stephen G. Machatha (Age 43)Ph.D., Senior Vice President, Technical Operation Key CompetitorsPyxis OncologyNASDAQ:PYXSscPharmaceuticalsNASDAQ:SCPHOptiNoseNASDAQ:OPTNNektar TherapeuticsNASDAQ:NKTRAdicet BioNASDAQ:ACETView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 740,177 shares on 3/11/2024Ownership: 6.668%Todd C BradySold 97,914 sharesTotal: $320,178.78 ($3.27/share)Bruce GreenbergSold 13,201 sharesTotal: $45,015.41 ($3.41/share)Goldman Sachs Group Inc.Sold 21,203 shares on 3/1/2024Ownership: 0.251%Perceptive Advisors LLCSold 2,756,499 shares on 2/26/2024Ownership: 14.610%View All Insider TransactionsView All Institutional Transactions ALDX Stock Analysis - Frequently Asked Questions Should I buy or sell Aldeyra Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALDX shares. View ALDX analyst ratings or view top-rated stocks. What is Aldeyra Therapeutics' stock price target for 2024? 3 equities research analysts have issued twelve-month price targets for Aldeyra Therapeutics' stock. Their ALDX share price targets range from $8.00 to $15.00. On average, they predict the company's stock price to reach $12.33 in the next twelve months. This suggests a possible upside of 300.4% from the stock's current price. View analysts price targets for ALDX or view top-rated stocks among Wall Street analysts. How have ALDX shares performed in 2024? Aldeyra Therapeutics' stock was trading at $3.51 at the beginning of the year. Since then, ALDX stock has decreased by 12.3% and is now trading at $3.08. View the best growth stocks for 2024 here. Are investors shorting Aldeyra Therapeutics? Aldeyra Therapeutics saw a drop in short interest in March. As of March 15th, there was short interest totaling 1,830,000 shares, a drop of 5.7% from the February 29th total of 1,940,000 shares. Based on an average daily volume of 544,400 shares, the days-to-cover ratio is presently 3.4 days. Currently, 3.2% of the company's stock are short sold. View Aldeyra Therapeutics' Short Interest. When is Aldeyra Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ALDX earnings forecast. How were Aldeyra Therapeutics' earnings last quarter? Aldeyra Therapeutics, Inc (NASDAQ:ALDX) issued its quarterly earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.01. During the same quarter last year, the company posted ($0.23) EPS. What ETF holds Aldeyra Therapeutics' stock? Invesco Dorsey Wright Healthcare Momentum ETF holds 172,465 shares of ALDX stock, representing 0.81% of its portfolio. What other stocks do shareholders of Aldeyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI). Who are Aldeyra Therapeutics' major shareholders? Aldeyra Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (14.61%), Vanguard Group Inc. (6.68%), Vanguard Group Inc. (6.67%), Verition Fund Management LLC (2.25%), Dimensional Fund Advisors LP (1.77%) and Eagle Asset Management Inc. (1.72%). Insiders that own company stock include Bruce Greenberg, Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc and Todd C Brady. View institutional ownership trends. How do I buy shares of Aldeyra Therapeutics? Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALDX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.